ADCT
Adc Therapeutics SA

1,235
Mkt Cap
$501.75M
Volume
533,797.00
52W High
$4.80
52W Low
$1.05
PE Ratio
-2.84
ADCT Fundamentals
Price
$4.46
Prev Close
$4.63
Open
$4.61
50D MA
$3.79
Beta
1.45
Avg. Volume
875,497.48
EPS (Annual)
-$1.62
P/B
-2.52
Rev/Employee
$267,309.43
Loading...
Loading...
News
all
press releases
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics to Present at November Investor Conferences ADC Therapeutics to Present at November Investor Conferences PR Newswire LAUSANNE, Switzerland, Oct. 27, 2025 LAUSANNE, Switzerland, Oct...
PR Newswire·6d ago
News Placeholder
More News
News Placeholder
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zacks·20d ago
News Placeholder
ADC Therapeutics Announces $60 Million Private Placement
ADC Therapeutics Announces $60 Million Private Placement ADC Therapeutics Announces $60 Million Private Placement PR Newswire LAUSANNE, Switzerland, Oct. 13, 2025 LAUSANNE, Switzerland, Oct. 13, 2025...
PR Newswire·20d ago
News Placeholder
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·2mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -900.00% and +13.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Feb. 3, 2025 LAUSANNE...
PR Newswire·9mo ago

Latest ADCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.